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SOX9 is an evolutionary conserved transcription factor that is expressed in a variety of tissues, with essential functions in cartilage, testis,
heart, glial cell, inner ear and neural crest development. By comparing human and pufferfish genomic sequences, we previously identified eight
highly conserved sequence elements between 290 kb 5V and 450 kb 3V to human SOX9. In this study, we assayed the regulatory potential of
elements E1 to E7 in transgenic mice using a lacZ reporter gene driven by a 529 bp minimal mouse Sox9 promoter. We found that three of these
elements and the Sox9 promoter control distinct subsets of the tissue-specific expression pattern of Sox9. E3, located 251 kb 5V to SOX9, directs
lacZ expression to cranial neural crest cells and to the inner ear. E1 is located 28 kb 5V to SOX9 and controls expression in the node, notochord,
gut, bronchial epithelium and pancreas. Transgene expression in the neuroectoderm is mediated by E7, located 95 kb 3V to SOX9, which regulates
expression in the telencephalon and midbrain, and by the Sox9 minimal promoter which controls expression in the ventral spinal cord and
hindbrain. We show that E3-directed reporter gene expression in neural crest cells of the first but not of the second and third pharyngeal arch is
dependent on beta-catenin, revealing a complex regulation of Sox9 in cranial neural crest cells. Moreover, we identify and discuss highly
conserved transcription factor binding sites within enhancer E3 that are in good agreement with current models for neural crest and inner ear
development. Finally, we identify enhancer E1 as a cis-regulatory element conserved between vertebrates and invertebrates, indicating that some
cis-regulatory sequences that control developmental genes in vertebrates might be phylogenetically ancient.
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Mutations in the human transcription factor gene SOX9 cause
the skeletal malformation syndrome campomelic dysplasia (CD)
with associated XY sex reversal (Wagner et al., 1994; Foster et
al., 1994). Accordingly, Sox9 has been shown to be a master
regulator of chondrogenesis and testogenesis in the mouse (Bi et0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Berlin, Germany.al., 1999; Akiyama et al., 2002; Chaboissier et al., 2004). CD
patients also show defects in other organ systems where Sox9 is
expressed (Ng et al., 1997) such as the inner ear, brain, pancreas
and heart (Houston et al., 1983;Mansour et al., 1995;Mansour et
al., 2002), implying a wider role for Sox9 in organogenesis.
Among the symptoms seen in CD are deafness, Robin sequence
(micrognathia, cleft palate and glossoptosis) and scoliosis,
which, apart from defects in chondrocyte development, could
also result from defective development of the otic vesicles, of
cranial neural crest cells (CNCCs) and of the notochord,
respectively. Indeed, studies in zebrafish, Xenopus and chicken
revealed essential functions for Sox9 in inner ear and cranial
neural crest development (Spokony et al., 2002; Cheung and
Briscoe, 2003; Liu et al., 2003; Saint-Germain et al., 2004).
Furthermore, a frequent symptom seen in CD patients is91 (2006) 382 – 397
www.e
S. Bagheri-Fam et al. / Developmental Biology 291 (2006) 382–397 383macrocephaly with dilatation of the lateral ventricles, and, in
about 25% of CD patients, the olfactory tracts and bulbs are
missing, indicating an important role for SOX9 in brain
development (Mansour et al., 1995). In mice, Sox9 is a major
determinant of oligodendrocytes and astrocytes in the ventral
neural tube, the two main types of glial cells in the central
nervous system (Stolt et al., 2003). A role for human SOX9 has
also been proposed in pancreas development, as in all three CD
patients analyzed, the pancreatic islets were less clearly formed
and expression of the hormones insulin and glucagon was
reduced to a variable degree (Piper et al., 2002). Finally, in
accordance with the observed heart defects in CD patients, it has
been shown that Sox9 is needed for the formation of the
endocardial cushions in mice and that homozygous Sox9 knock-
out mice die at 11.5 days post-coitum (dpc) from heart failure
(Akiyama et al., 2004).
These data show that Sox9 has essential early functions in
the specification and/or differentiation of various tissues. The
identification of the cis-regulatory elements controlling SOX9
expression in these different tissues would greatly enhance the
characterization of the trans-acting factors binding to these
elements, allowing for a better definition of the regulatory
network that specifies cells/organs like chondrocytes, testis,
cranial neural crest cells, the otic placode and glial cells in
humans or mice. The search for such SOX9 cis-regulatory
elements has turned out to be challenging because SOX9 has
an extended regulatory region as indicated by CD transloca-
tion breakpoints that are scattered up to 1 Mb 5V to SOX9
(Pfeifer et al., 1999). An initial study by Wunderle et al.
(1998) approached the identification of these long-range
elements by generating mice transgenic for human SOX9-
lacZ yeast artificial chromosomes (YACs) which contained
variable amounts of DNA sequences 5V to SOX9. They could
show that the CD translocation breakpoints most likely
remove multiple cis-regulatory elements from the human
SOX9 gene and that most of these elements should reside
within a 600-kb interval extending 350 kb 5V and 250 kb 3V to
SOX9 (Wunderle et al., 1998). Moreover, they could define
genomic subregions where tissue-specific enhancers should be
located. However, with none of their transgenic YACs could
they detect lacZ expression in the developing male gonads,
implying that either the human sequences are not functional
in the mouse or that the testis-specific enhancer(s) are located
outside the 600-kb interval. By comparing 2.5 Mb of human
with 195 kb of pufferfish (Takifugu rubripes) genomic
sequences around the Sox9 locus, we previously identified
five highly conserved sequence elements, E1–E5, up to 290
kb 5V to human SOX9, and two such elements, E6 and E7, up
to 95 kb 3V to human SOX9. These elements all reside within
the interval identified by Wunderle and co-workers. Only
element E8, located 450 kb 3V to SOX9, lies outside this
interval. Most of these putative long-range cis-regulatory
elements are around 100–150 bp in size, showing 68% to
80% sequence identity between human, mouse and Takifugu
(Bagheri-Fam et al., 2001).
In this study, we have assayed the regulatory potential of
elements E1 to E7 in transgenic mice, using lacZ as areporter gene that was driven by a minimal mouse Sox9
promoter (Kanai and Koopman, 1999). We show that three
of these elements, E3, E1 and E7, and the Sox9 promoter
itself can drive lacZ gene expression in a tissue-specific
manner that recapitulates the endogenous Sox9 expression
pattern in various tissues including the cranial neural crest,
inner ear, brain, ventral neural tube/hindbrain, node, noto-
chord, gut, pancreas and bronchial epithelium. Moreover, we
demonstrate that Sox9 expression in a subset of CNCCs is
dependent on beta-catenin and discuss highly conserved
protein binding sites for enhancer E3 that are in good
agreement with current models for cranial neural crest and
inner ear development. Finally, we identify enhancer E1 as a
cis-regulatory element conserved between vertebrates and
invertebrates.
Material and methods
Generation of DNA constructs for microinjection
The conserved human elements E1–E7 with their 5V- and 3V-flanking
sequences and the minimal mouse Sox9 promoter (see below) were
amplified by PCR with the proofreading polymerase Pfu using human and
mouse genomic DNA, respectively. The oligonucleotides used for the PCR
reaction contained at their 5V-end a restriction site for the subsequent cloning
of the PCR product preceded by 2–6 nucleotides to facilitate the restriction
digest. Digested PCR fragments E1 to E5 and the Sox9 promoter were
subcloned into the multiple cloning site of pBS SK (Stratagene) in order to
generate constructs containing the mouse Sox9 promoter with elements E1–
E5 either as single fragments or in combination. The constructs generated
within pBS SK were released with the restriction enzymes SpeI and XhoI
and subcloned into the lacZ reporter vector pCMVß (CLONTECH). By this
cloning step, the CMV promoter of the pCMVß vector was replaced by the
element-Sox9 promoter construct. Elements E6 and E7 were directly cloned
as SpeI fragments into the pCMVß vector that already contained the Sox9
promoter. The pCMVß vector used for our transgenic studies was a
modification from the original vector with an insertion of a 40 bp EcoRI–
SalI –SmaI –SpeI –EcoRI fragment into the EcoRI site. All finished
constructs were sequenced using the ABI310 automated fluorescence
sequencer in order to confirm the correct sequence, orientation and order
of the different DNA fragments.
Constructs and primer sequences
Nucleotides in bold denote the restriction sites added to the 5V end, with the
corresponding restriction enzyme given in brackets; nucleotides added to the 5V
end to facilitate restriction are underlined. In all constructs, the lacZ gene is
driven by the minimal 529 bp mouse Sox9 promoter (Sox9P).
Construct Sox9P (529 bp) contains only the minimal mouse Sox9 promoter
(529 bp) that was amplified with primers 5V-GAATCGATACCTCTGGCT-
GAGCTCC-3V (ClaI) and 5V-AGCTCGAGGAAGGCGAGAAGCCGC-3V
(XhoI).
Construct E1Sox9P (1045 bp) contains the DNA fragment E1 (516 bp),
consisting of element E1 (130 bp) extended by 206 bp in 5V and by 180 bp in 3V
direction, that was amplified with primers 5V-GTATCGATAGACCAACTTT-
CAAATATGCC-3V (ClaI) and 5V-GTATCGATACAATTCATTCAGTCCAC-3V
(ClaI).
Construct E2Sox9P (1021 bp) contains the DNA fragment E2 (492 bp), consisting
of element E2 (123 bp), extended by 189 bp in 5V and by 180 bp in 3V direction, thatwas
amplified with primers 5VAGGAATTCAAAGGCCATTGATCCTCC-3V (EcoRI) and
5V-GTATCGATACACTTTTGATTGTACTGTGG-3V (ClaI).
Construct E3Sox9P (1062 bp) contains the DNA fragment E3 (533 bp),
consisting of element E3 (139 bp), extended by 144 bp in 5V and by 250 bp in 3V
direction, that was amplified with primers 5V-AGGAATTCCTGGTCAAG-
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CATGATTC-3V (ClaI).
Construct E4Sox9P (1050 bp) contains the DNA fragment E4 (521 bp),
consisting of element E4 (157 bp), extended by 170 bp in 5V and by 194 bp in 3V
direction, that was amplified with primers 5V-AACCTGCAGTCCTTG-
CAAAGGTAGTCC-3V (PstI) and 5V-AGGAATTCTCCTCTGTCAGCATG-
CAG-3V (EcoRI).
Construct E5Sox9P (956 bp) contains the DNA fragment E5 (427 bp),
consisting of element E5 (129 bp), extended by 129 bp in 5V and by 169 bp in 3V
direction, that was amplified with primers 5V-GGACTAGTTCCAAACAGC-
CACAGTTATC-3 V (Spe I ) and 5 V-AAACTGCAGGAGGTGCT-
TATGTGGCTG-3V (PstI).
Construct E6Sox9P (910 bp) contains the DNA fragment E6 (381 bp),
consisting of element E6 (97 bp), extended by 129 bp in 5V and by 155 bp in 3V
direction, that was amplified with primers 5V-ATCTAGACTAGTCTTCTGTT-
TACACCTGAG-3 V (Spe I) and 5 V-ATCTAGACTAGTTGGACTC-
GAAGGCTCTG-3V (SpeI).
Construct E7Sox9P (1667 bp) contains the DNA fragment E7 (1138 bp),
consisting of element E7 (403 bp), extended by 453 bp in 5V and by 282 bp in 3V
direction, that was amplified with primers 5V-ATCTAGACTAGT-
GAAAGCTCCGAAGGACTC-3V (SpeI) and 5V-ATCTAGACTAGTGTTC-
GAAGGCAGCCTTAG-3V (SpeI).
Construct E5–E3Sox9P (2010 bp) contains the DNA fragments E3–E5.
Production and genotyping of transgenic mice
For microinjection, lacZ fusion gene constructs were separated from vector
sequences by cutting with the restriction enzyme SalI followed by electropho-
resis on 1% Seakem\ GTG\-Agarose gels (Biozym), and excised insert
fragments were purified with the QIAquick\ PCR Purification Kit (Qiagen).
The purified constructs were microinjected into the male pronuclei of fertilized
FVB mouse oocytes using standard procedures (Hogan et al., 1994). Transgenic
embryos and transgenic founder animals were identified by PCR with the lacZ
primers 5V-CTGCGATGTCGGTTTCCG-3V and 5V-GGATGGTTCGGA-
TAATGCG-3V using Proteinase K-digested yolk sacs and tail biopsies as
DNA templates, respectively. To establish transgenic lines, founder animals
were crossed with C57BL/6 wildtype mice.
Whole-mount ß-galactosidase staining and histological analysis
Whole-mount ß-galactosidase staining of 6.5 to 13.5 dpc embryos using X-
gal as a substrate was performed as described (Hogan et al., 1994). 12.5 dpc
and 13.5 dpc embryos were cut transversally prior to whole-mount ß-
galactosidase staining to facilitate penetrance of X-gal at these stages. After
whole-mount staining, embryos were embedded in paraffin and 10-Am sections
were prepared. Staining was from 5 min to overnight depending on the strength
of transgene expression.
Generation of Wnt1-Cre;beta-cat floxdel/flox;E5–E3Sox9P embryos
Wnt1-Cre;beta-cat floxdel/+ male mice in which one copy of the beta-catenin
gene is inactivated and in which the Cre recombinase is under the control of the
Wnt1 promoter (Brault et al., 2001) were crossed with female mice carrying
construct E5–E3Sox9P (this study). Resultant Wnt1-Cre;beta-cat floxdel/+ ;E5–
E3Sox9P male mice were crossed with female beta-cat flox/flox mice in which
both beta-catenin gene copies are flanked by loxP sites (Brault et al., 2001) to
generate Wnt1-Cre;beta-cat floxdel/flox;E5–E3Sox9P embryos. For genotyping,
DNA from tail biopsies was analyzed by PCR using primers for Cre and beta-
catenin as described (Brault et al., 2001).
SOX9 immunohistochemistry on paraffin and cryosections
C57BL/6 wildtype embryos were used for immunohistological analyses.
For paraffin sections, embryos were collected in PBS, fixed in Serra
(ethanol:37% formaldehyde:acetic acid, 6:3:1) at 4-C overnight, dehydrated
through an ascending ethanol series, embedded in paraffin and sectioned at 7
Am. For cryosections, embryos were collected in PBS and fixed in freshlyprepared 4% paraformaldehyde in PBS at 4-C overnight. The embryos were
incubated in 15% sucrose for 2 h at 4-C followed by incubation in 30% sucrose
at 4-C overnight. The embryos were then embedded in Tissue Freezing
Medium (Jung) and frozen in a liquid nitrogen bath. 10–15-Am sections were
collected on SuperFrost slides (Roth) using a cryostat at 20-C and dried at
room temperature. For SOX9 immunohistochemistry on paraffin and frozen
sections, the Peroxidase Rabbit IgG Vectastain\ ABC Kit (Vector) was used
following the instructions of the manufacturer. The primary rabbit anti-SOX9
antibody (kind gift of M. Wegner) was applied at 1:200 dilution on the sections.
Results
In this study, we have assayed the regulatory potential of the
putative human long-range SOX9 cis-regulatory elements E1 to
E7 in transgenic mice using lacZ as a reporter gene that was
driven by a minimal mouse Sox9 promoter (Kanai and Koop-
man, 1999). We first examined the regulatory potential of the
minimal mouse Sox9 promoter which has been described to be,
at least in part, responsible for testis-specific expression of the
Sox9 gene in vitro (Kanai and Koopman, 1999). In order to
investigate the effects of the potential human enhancers E1 to E7
on mouse Sox9 promoter activity, we performed a series of
transgenic assays with DNA constructs containing these
elements either as single DNA fragments or in combination.
As the sequence conservation of elements E1 to E7 between
human and mouse extends beyond the 80–120 bp of sequence
conserved between human or mouse and pufferfish, we included
additional 5V and 3V sequences flanking the highly conserved
elements in our transgenic analyses (Fig. 1). LacZ expression of
the different constructs was compared to the previously
described Sox9 gene expression pattern (Ng et al., 1997; Zhao
et al., 1997). As Sox9 expression in some tissues such as gut and
lung had so far not been studied in detail, we performed
immunohistochemistry in these tissues using a SOX9 antibody.
The 529 bp minimal mouse Sox9 promoter controls early gene
expression in the ventral spinal cord and ventral hindbrain
The mouse Sox9 promoter used in our study spans 529 bp of
genomic DNA and extends 202 bp 5V and 327 bp 3V relative to
the transcription start site (construct Sox9P). In contrast to
human elements E1 to E8 that are highly conserved in Takifugu
(Bagheri-Fam et al., 2001 and Figs. 6A and B), the mouse Sox9
promoter is well conserved only in human and shows some
sequence similarity to chicken (Kanai and Koopman, 1999). Of
the two established transgenic mouse lines, none expressed the
transgene between 6.5 and 13.5 dpc. However, 4 of 11 transient
transgenic embryos showed a very restricted reporter gene
expression in the ventral hindbrain and ventral neural tube at 9.5
dpc and 10.5 dpc (Fig. 2). As all lacZ expressing transgenic
mouse lines established in this study exhibited an almost
identical expression pattern in the ventral hindbrain and ventral
neural tube (Fig. 1), we could study the spatiotemporal
expression controlled by the Sox9 promoter in detail.
During the development of the spinal cord, the mouse SOX9
protein is initially detected at 9.5 dpc in the ventral neural tube
(Fig. 2C and Stolt et al., 2003). From 10.5 dpc on, SOX9 protein
expression is found in the proliferating ventricular zone
Fig. 1. Conserved sequence elements from the human SOX9 locus function as tissue-specific enhancers in transgenic mouse embryos. (A) Position of conserved
sequence elements located 5V (E1–E5) and 3V (E6 and E7) to the human SOX9 gene, with distances given in kb. The direction of transcription of the SOX9 gene is
indicated by an arrow. (B) Summary of constructs, transgenic lines or embryos and observed expression pattern. Elements E1 to E7 were assayed either as single
DNA fragments or in combinations for their regulatory potential in transgenic mice using a lacZ reporter gene driven by a 529 bp minimal mouse Sox9 promoter.
The shaded box within the Sox9 promoter represents the region 3V to the transcription start site. As the sequence conservation of elements E1 to E7 between human
and mouse extends beyond the 80–120 bp of sequence conserved between human or mouse and pufferfish (black boxes), additional 5V- and 3V-flanking sequences
were included (white boxes). The first column at left gives the name of the construct, the second column indicates the number of lines or embryos with ß-gal activity
(#expressing), the third column indicates the total number of transgenic lines or embryos (#Tg) and the fourth column denotes the stages in dpc (days post-coitum) at
which the transgenic embryos were analyzed. The tissues expressing the lacZ transgene are listed at right. Note that for construct E5Sox9P no expressing transgenic
line/transient transgenic embryo could be obtained (n.a., not analyzed).
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early and restricted expression of SOX9 at 9.5 dpc, ß-
galactosidase staining was first weakly visible at 9.5 dpc in the
ventral neural tube, extending from the hindbrain to the spinal
cord beyond the forelimb bud level (Figs. 2A and B). At 10.5
dpc, transgene expression was up-regulated and extended up to
the hindlimb bud level (Figs. 2D and E). However, except for a
small region in the ventral part, no transgene expression was
detected at 10.5 dpc and at later stages in the SOX9-expressing
ventricular zone (compare Fig. 2E with Fig. 2F, and data not
shown). Thus, the Sox9 promoter fragment can mediate only the
early aspect of SOX9 expression in the spinal cord andhindbrain. The delay of strong ß-galactosidase staining in the
ventral part of the neural tube by 1 day in comparison to the
SOX9 protein may be explained by the fact that some time is
needed for the ß-galactosidase protein to accumulate in these
cells. It should be mentioned that no expression, at any stage
analyzed, could be detected in the testis.
Enhancer E1 mediates expression in the node, notochord, gut,
bronchial epithelium and pancreas
The conserved 116 bp element E1 (Fig. 6A), located 28 kb 5V
to human SOX9, was cloned as a 516 bp fragment in front of the
Fig. 2. The 529 bp mouse Sox9 promoter mediates lacZ expression in the early ventral hindbrain and early ventral spinal cord. (A and D) Whole-mount ß-
galactosidase staining and (B and E) paraffin transverse sections of transient transgenic embryos carrying construct Sox9P. (C and F) SOX9 immunohistochemistry
on cryosections. The arrows in A and D indicate the posterior expression boundary in the spinal cord. The Sox9 promoter initiates lacZ expression in the ventral
hindbrain/spinal cord at 9.5 dpc (A and B). Up-regulated lacZ expression was observed in both the hindbrain and spinal cord at 10.5 dpc (D and E). Abbreviations
used: hb, hindbrain; sc, spinal cord; vz, ventricular zone.
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could establish three expressing transgenic mouse lines which
all exhibited a similar expression pattern. Enhancer E1 mediated
lacZ expression in a variety of tissues with an expression pattern
closely resembling that of endogenous Sox9/SOX9 (Fig. 3).
Similar to endogenous Sox9 expression (Ng et al., 1997),
lacZ expression was first detected in the node at 7.5 dpc (Fig.
3A) and at 8.25 dpc also in the notochord (Fig. 3B). Expression
of ß-galactosidase and of SOX9 protein in the notochordal plate
and notochord continued through subsequent development
(Figs. 3D–M) at least until 13.5 dpc (data not shown). At 8.5
dpc, we could also detect strong lacZ expression in mesodermal
cells immediately lateral to the notochordal plate (Fig. 3D,
inset), similar to endogenous Sox9 (Ng et al., 1997).
Like the SOX9 protein, ß-galactosidase staining in the gut
was already observed at 8.5 dpc (Figs. 3D–G). However, while
the reporter gene seemed to be uniformly expressed from
anterior to posterior (Figs. 3D and E), the SOX9 protein, while
clearly detectable in the posterior region, was only barely
detectable in the anterior region of the gut (Figs. 3F and G).
This difference in expression pattern could also be seen at later
stages. Thus, from 9.5 dpc on, lacZ was almost equally highly
expressed in the esophagus, stomach, duodenum and hindgut
(Figs. 3H, I, L and O), while SOX9 protein expression was
significantly weaker in the esophagus than in the more distal
parts of the gut (Figs. 3J, K, M and P).The expression pattern of ß-galactosidase and of SOX9 was
almost identical, however, during lung development. Both
proteins were already detectable at 9.5 dpc in the laryngo-
tracheal groove of the foregut (Figs. 3I and K). By 11.0 dpc, ß-
galactosidase/SOX9 expression could be seen in the bronchial
epithelium of the two lung buds (Figs. 3L and M). Later on, the
expression of both proteins was lost in the two main bronchi
and was confined to the newly forming bronchial branches of
the lung (Fig. 3N and data not shown).
LacZ expression was also observed in the developing
pancreas. Similar to endogenous Sox9 (Lioubinski et al.,
2003), the ß-galactosidase protein was already present when
the pancreatic buds first become visible at 9.5–10.0 dpc (Fig.
3C). Histological sections of 11.0 dpc transgenic embryos
showed that ß-galactosidase was expressed, like SOX9, in the
epithelium of both pancreatic buds (Figs. 3O and P). At 13.5
dpc, the reporter gene was still strongly expressed in the
entire pancreatic epithelium (Fig. 3Q), similar to Sox9
(Lioubinski et al., 2003).
Apart from these specific sites of expression recapitulat-
ing endogenous Sox9/SOX9 expression, in all three expres-
sing lines analyzed, we observed ectopic reporter gene
expression in the floor plate (Fig. 3L), in cells surrounding
the neural tube (data not shown), within the presomitic
mesoderm (data not shown) and in the newly formed
somites (Fig. 3C).
Fig. 3. Enhancer E1 is responsible for transgene expression in the node, notochord, gut, bronchial epithelium and in the pancreas. (A–C) Whole-mount ß-
galactosidase staining, (N) dissected lung after whole-mount ß-galactosidase staining and (D, E, H, I, L, O, Q) paraffin transverse sections of transgenic embryos
carrying construct E1Sox9P. (F, G, J, K, M, P) SOX9 immunohistochemistry on cryosections. The arrows in the inset of D indicate ß-galactosidase-positive cells in
paraxial mesodermal cells immediately lateral to the notochordal plate. Note that, from 8.5 dpc on, lacZ expression is present throughout the entire gut (D, E, H, I, L,
O), while SOX9 protein expression is hardly detectable in the foregut (G) but is specifically initiated in the laryngo-tracheal groove of the foregut at 9.5 dpc (arrows
in K). Abbreviations used: be, bronchial epithelium; d, duodenum; dp, dorsal pancreatic primordium; e, esophagus; fg, foregut; fp, floor plate; g, gut; hg, hindgut; llp,
left lobe of pancreas; ltg, laryngo-tracheal groove; n, node; nc, notochord; np, notochordal plate; p, pancreas; rlp, right lobe of pancreas; s, stomach; vp, ventral
pancreatic primordium.
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and in the inner ear
The regulatory potential of DNA fragments E5 (427 bp), E4
(521 bp) and E3 (533 bp) containing the conserved elements
E5 (129 bp), E4 (157 bp) and E3 (139 bp), respectively, was
first tested in combination (construct E5–E3Sox9P, Fig. 1).Two expressing transgenic mouse lines could be established
which exhibited a similar lacZ expression pattern in CNCCs
and in the developing inner ear (Fig. 4), where endogenous
Sox9 is strongly expressed (Ng et al., 1997).
Sox9 expression in CNCCs has been reported to initiate as
early as 8.0 dpc (Takahashi et al., 2001). In agreement with this
early expression, E5–E3-directed lacZ expression was first
S. Bagheri-Fam et al. / Developmental Biology 291 (2006) 382–397388weakly detectable at the dorsal tips of the hindbrain neural
folds at 7.75 dpc (Fig. 4A), becoming up-regulated after 8.0
dpc (Figs. 4B and E). At 8.5 dpc, both SOX9 and ß-
galactosidase were expressed in pre-migratory CNCCs at the
dorsal tips of the hindbrain neural folds, in migrating CNCCs
immediately contiguous to these dorsal edges outside the
neural tube and in CNCCs within the first and secondFig. 4. Constructs E5–E3Sox9P and E3Sox9P direct lacZ expression to CNCCs and
I, K) paraffin transverse sections of transgenic embryos carrying construct E5–E3
Whole-mount ß-galactosidase staining of transgenic embryos carrying construct E3S
early as 7.75 dpc (A). In contrast to construct E5–E3Sox9P (O), construct E3Sox9P
However, construct E3Sox9P expresses the lacZ gene in a manner similar to construc
the dorsal tips of the hindbrain, in migrating CNCCs and in CNCCs within the phary
second pharyngeal arch; ba3, third pharyngeal arch; ba4, fourth pharyngeal arch; b
process of the first pharyngeal arch; CNC, cranial neural crest; CNCC, cranial neu
vesicle; r2, rhombomere 2; r3, rhombomere 3; r4, rhombomere 4.pharyngeal arches (Figs. 4B, E and F and data not shown).
However, the SOX9 protein exhibited a broader expression
pattern than ß-galactosidase that included the more anteriorly
located cranial NCCs of the forebrain and midbrain and the
more posteriorly located trunk NCCs (data not shown). At 9.5
dpc, both SOX9 and ß-galactosidase were strongly expressed
in migrating CNCCs originating from rhombomeres 2 and 4to the inner ear. (A–D and O) Whole-mount ß-galactosidase staining and (E, G,
Sox9P. (F, H, J, L) SOX9 immunohistochemistry on cryosections. (M and N)
ox9P. Note that lacZ expression at the dorsal tips of the hindbrain can be seen as
(M and N) shows only very weak expression in the CNCCs and in the inner ear.
t E5–E3Sox9P (the three arrows in N and O indicate similar lacZ expression at
ngeal arches, respectively). Abbreviations used: ba1, first pharyngeal arch; ba2,
a1 (mx), maxillary process of the first pharyngeal arch; ba1 (mn), mandibular
ral crest cells; ed, endolymphatic duct; op, otic pit; opl, otic placode; ov, otic
S. Bagheri-Fam et al. / Developmental Biology 291 (2006) 382–397 389and within the first, second and third pharyngeal arches (Figs.
4C, G and H and data not shown). At 10.5 dpc, ß-galactosidase
continued to be expressed in the CNCCs of the pharyngeal
arches (Fig. 4D), as did the SOX9 protein (not shown).
Regarding inner ear development, the transgene was
already strongly expressed at 8.0–8.5 dpc in the otic placode
(Figs. 4B and I), consistent with the early endogenous
expression of SOX9 (Fig. 4J). At 9.0 dpc (data not shown)
and 9.5 dpc, high reporter gene expression could be found in
the invaginating otic placode (otic pit) and in the entire otic
vesicle, respectively (Figs. 4C and K). In contrast, the SOX9
protein showed stronger expression in the medial part of the
otic vesicle at 9.5 dpc (Fig. 4L). At 10.5 dpc, the transgene
was still expressed in the otic vesicle and was also detectable
in the developing endolymphatic duct (Fig. 4D). From 11.0
dpc on, expression of lacZ decreased significantly and was
not detectable any more at 12.5 dpc (data not shown),
similar to endogenous Sox9 (Ng et al., 1997).
In order to determine the element(s) responsible for the
expression in the cranial neural crest and in the inner ear, we
examined reporter constructs containing DNA fragments E5,
E4 and E3 as single DNA fragments (constructs E5Sox9P,
E4Sox9P and E3Sox9P, Fig. 1). Unfortunately, no expressing
line could be established for construct E5Sox9P. For construct
E4Sox9P, we generated three transgenic lines, two of which
expressed the transgene. As both lines only revealed the Sox9
promoter expression pattern (data not shown), E4 seems to
have no independent enhancer activity. Finally, for construct
E3Sox9P, we could establish six transgenic mouse lines of
which only one expressed the lacZ gene. Since transgene
expression was very weak in the E3 transgenic mouse line,
we could not analyze lacZ expression in the same detail as
we did for fragments E5–E3. However, we found that
enhancer E3 directed reporter gene expression exclusively to
CNCCs and to the inner ear from approximately 8.0 to 8.5
dpc on (Figs. 4M and N), similar to DNA fragments E5–E3
(Fig. 4O). This expression pattern was confirmed by an 8.5
dpc embryo transient transgenic for construct E3Sox9P (data
not shown). Thus, enhancer E3 seems to recapitulate at least
some if not all aspects of the expression pattern mediated by
fragments E5–E3.Fig. 5. Enhancer E7 drives transgene expression in the early telencephalon and ear
transverse sections of a 9.25 dpc transient transgenic embryo carrying construct E7Enhancer E7 regulates early SOX9 expression in the
telencephalon and midbrain
To obtain construct E7Sox9P (Fig. 1), we cloned a 1138
bp DNA fragment containing the conserved 403 bp element
E7 in front of the Sox9 promoter. The regulatory potential
of this construct was analyzed in transient transgenic
embryos at 9.25 dpc and 11.5 dpc. At 9.25 dpc, six out
of nine transgenic embryos showed strong ß-galactosidase
staining in the telencephalon and in the midbrain (Figs. 5A–
C). This expression is consistent with endogenous Sox9
which starts to be expressed in the forebrain neuroepithe-
lium as early as 8.5 dpc and is expressed in the midbrain
from 9.5 dpc on; at 11.5 dpc, Sox9 expression is confined
to the ventricular zone of the forebrain, midbrain, hindbrain
and spinal cord (Zhao et al., 1997). However, none of the
three out of six transgenic lacZ-expressing embryos at 11.5
dpc showed ß-galactosidase staining in the ventricular zone,
indicating that enhancer E7 can only mediate the early
aspect of Sox9 expression in the telencephalon and in the
midbrain.
Like E4, elements E2 and E6 have no independent enhancer
activity
We assayed a construct with a 492 bp DNA fragment
containing human sequence element E2 (123 bp) (construct
E2Sox9P, Fig. 1). Four of the eleven established transgenic
mouse lines expressed the lacZ gene. However, all four
lines only showed the Sox9 promoter expression pattern
(data not shown). We also assayed a construct with a 381
bp DNA fragment containing the conserved 97 bp element
E6 (construct E6Sox9P, Fig. 1). The regulatory potential of
this construct was only analyzed in transient transgenic
embryos at 11.5 dpc. Three out of five transgenic embryos
expressed the lacZ gene. Again, all three embryos exclu-
sively showed the Sox9 promoter expression pattern (data
not shown). Therefore, like E4 (see above), E2 and E6 do
not seem to have an independent enhancer activity; however,
it is still possible that E6 has a regulatory potential at earlier
or later embryonic stages.ly midbrain. (A) Whole-mount ß-galactosidase staining and (B and C) paraffin
Sox9P. Abbreviations used: mb, midbrain; tel, telencephalon.
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factor binding sites within enhancer E1 and E3
By using the online program MatInspector (Quandt et al.,
1995; www.genomatix.de) and by visual inspection, the
enhancers E3, E1 and E7 and the Sox9 promoter were
searched for potential DNA binding sites for transcription
factors that are expressed in the ß-galactosidase-positive
tissues of the transgenic embryos before or concomitant with
Sox9 expression.
In agreement with the lacZ expression pattern of enhancer
E1 in the node, notochord, gut, bronchial epithelium and
pancreas, we previously identified a highly conserved binding
site for the transcription factor Foxa2 (Hnf3ß) (Bagheri-Fam et
al., 2001) that is co-expressed with Sox9 in all these tissues
(Monaghan et al., 1993; Ng et al., 1997). While the mouse and
Takifugu FOXA2 binding sites differ only by one base, the
human FOXA2 binding site is identical to the 12 bp Foxa2
consensus sequence (C/G)AAT(G/A)TTTG(C/T)(C/T)(C/T)
(Overdier et al., 1994; Fig. 6A).
In agreement with the lacZ expression pattern of enhancer
E3, we could identify several binding sites conserved
between human, mouse and Takifugu for transcription factors
that play a central role in the development of the cranial
neural crest and of the inner ear. In close proximity to each
other, we found binding sites for Tcf/Lef1 (mediators of the
canonical Wnt signaling pathway), Ets (mediators of the FGF
signaling pathway), Gli (mediators of the Shh signaling
pathway)/Krox20, Dlx, Otx and two binding regions for the
trimeric protein complex Meis/Pbx/Hox1–5. Furthermore, we
identified an AP2 binding site that is only conserved
between human and mouse. Remarkably, all these human
and mouse transcription factor binding sites differ by only
one base from or are even identical to the described
consensus binding sites (Fig. 6B).
Within enhancer E7 (forebrain/midbrain) and the Sox9
promoter (ventral hindbrain/spinal cord), we also found
some conserved transcription factor binding sites (data not
shown), but none of these transcription factors could be
specifically correlated with the observed lacZ expression
pattern.
Enhancer E1 has evolved prior to the separation of the
Deuterostomia and Protostomia lineages 700 million years ago
The Drosophila gene Sox100B, the likely precursor of
the vertebrate group E Sox genes Sox8, Sox9 and Sox10,
has been shown to share some aspects of the tissue-specific
expression pattern with the group E Sox genes, in particular
in gut (Loh and Russell, 2000). As the evolutionarily highly
conserved element E1 mediates strong reporter gene
expression in the murine gut, we speculated that some
sequences of this enhancer could be conserved in Drosoph-
ila. By visual inspection, we analyzed genomic sequences
around the proto SoxE gene of Drosophila and of the
urochordate Ciona intestinalis, the lineages of which
separated approximately 700 and 550 million years agofrom the vertebrate lineage, respectively. We indeed found
some sequence similarity to element E1 in both species,
with remarkable conservation of the Foxa2 binding site
(Fig. 6A). While in Ciona this sequence resides approxi-
mately 55 kb 5V to the SoxE gene, in Drosophila, this
sequence is located only 3 kb 3V to Sox100B. The relatively
large distance between element E1 and the Ciona SoxE
gene may be incorrect since the genomic Ciona sequences
are still in draft form. To better visualize the conservation
of element E1 between these evolutionarily distant species,
we subdivided this element into the conserved boxes A–K
(Fig. 6A). While the Foxa2 binding site and boxes A, D, F
and K are conserved from human to Drosophila, the boxes
C and I are only conserved up to Ciona, and boxes E, G,
H and J are vertebrate-specific. Furthermore, the inverte-
brates Ciona and Drosophila share a common sequence
element that differs from the vertebrate-specific box E, and,
finally, box B is specific for Takifugu , Ciona and
Drosophila.
Beta-catenin is essential for E5–E3-directed ß-galactosidase
protein expression in the first pharyngeal arch
It has been shown in Xenopus that Sox9 expression in
CNCCs is dependent on the canonical Wnt signaling pathway
(Luo et al., 2003). This pathway leads to the stabilization of
cytosolic beta-catenin, which then associates with TCF
transcription factors to regulate expression of Wnt-target
genes. As the cranial neural crest/inner ear-specific enhancer
E3 contains a highly conserved Tcf/Lef1-binding site (Fig.
6B), we speculated that this enhancer could be regulated by
the canonical Wnt pathway. To assess if the E3 enhancer-
mediated lacZ expression in the cranial neural crest is
dependent on beta-catenin in vivo, we crossed mice carrying
construct E5–E3Sox9P with mice where the beta-catenin gene
has been conditionally inactivated in CNCCs by the Cre
recombinase under the control of the Wnt1 promoter.
Inactivation of beta-catenin in these mice (Wnt1-Cre;beta-
cat floxdel/flox) was reported to start at 8.5 dpc, with complete
absence of beta-catenin protein in the pharyngeal arches at
9.25 dpc (Brault et al., 2001). We analyzed lacZ expression
of 8.5–9.5 dpc Wnt1-Cre;beta-cat floxdel/flox;E5–E3Sox9P em-
bryos and compared this expression with mice carrying only
construct E5–E3Sox9P. In embryos of the former genotype,
we observed a dramatic decrease or even a complete loss of
ß-galactosidase-positive cells migrating to and within the first
pharyngeal arch from 8.75 to 9.0 dpc on, while the total cell
number within the first pharyngeal arches seemed to be
unaltered compared to the E5–E3Sox9P embryos (compare
Figs. 7A and B with C and D). In contrast, the second and
third pharyngeal arches showed only a mild reduction in ß-
galactosidase staining intensity, and the total number of ß-
galactosidase-positive cells seemed to be unaltered. As
expected, ß-galactosidase staining was normal in control
tissues such as the otic vesicle, where beta-catenin has not
been inactivated (Figs. 7A and C). It seems that Wnt/beta-
catenin signaling is essential for E5–E3-directed lacZ
Fig. 6. Conservation of Sox9 E1 and E3 enhancer and promoter sequences indicates multiple transcription factor binding sites. (A) Sequence comparison of Sox9
enhancer E1 between human, mouse, Takifugu, Ciona and Drosophila that controls expression in the node, notochord, gut, bronchial epithelium and pancreas. A
potential FOXA2 binding site could be identified that is highly conserved even in Drosophila. To better visualize the conservation of element E1 between these
evolutionarily distant species, we have subdivided this element into conserved boxes A–K that are discussed in the text. Nucleotides in bold are exclusively
conserved between the invertebrates Ciona and Drosophila. (B) Sequence comparison of Sox9 enhancer E3 between human, mouse and Takifugu that mediates
expression in cranial NCCs and in the inner ear. This enhancer contains two potential binding sites for the trimer Meis/Pbx/Hox1–5 and for Otx and single binding
sites for Ap2 (only conserved between human and mouse), Ets, Tcf/Lef-1, Krox20/Gli and Dlx. Note that all human transcription factor binding sites differ only by
one base or are even identical to the consensus sequence. (C) Comparison of human and mouse SOX9/Sox9 promoter sequences with the V2 interneuron-specific
GATA2/Gata2 enhancer (Zhou et al., 2000) reveals several highly conserved sequence blocks. In panels A, B and C, conserved nucleotides are highlighted in gray,
gaps are shown by dashes and consensus sequences for the predicted transcription factor binding sites are indicated below the sequences. Except for Ap2 (Mitchell et
al., 1991) and Meis/Pbx/Hox1–5 (Shen et al., 1997), binding sites were taken from the online program MatInspector (www.genomatix.de).
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Fig. 7. E5–E3-directed ß-galactosidase protein expression in the first but not in the second and third pharyngeal arch is dependent on beta-catenin. (A) Whole-mount
ß-galactosidase staining and (B) paraffin transverse section of a 9.0 dpc and a 9.5 dpc transgenic embryo carrying construct E5–E3Sox9P. (C) Whole-mount ß-
galactosidase staining and (D) paraffin transverse section of a 9.0 dpc and a 9.5 dpc E5–E3Sox9P transgenic beta-catenin-deficient embryo (genotype: Wnt1-
Cre;beta-cat floxdel/flox;E5–E3Sox9P). The arrow in A and C points to CNCCs that migrate into the first pharyngeal arch. In beta-catenin-deficient embryos (C and
D), the number of ß-galactosidase-positive cells within the first pharyngeal arch is drastically reduced compared to wildtype (A and B) embryos, while, in the second
and third pharyngeal arches, ß-galactosidase staining intensity is only mildly reduced. Abbreviations used: ba1, first pharyngeal arch; ba2, second pharyngeal arch;
ba3, third pharyngeal arch; ov, otic vesicle.
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the second and third pharyngeal arches.
Discussion
Genomic organization of the SOX9 cis-regulatory domain
This study shows that SOX9 is regulated by a complex set of
widely spaced tissue-specific enhancers, located in the imme-
diate vicinity of the transcription start site, up to 251 kb 5V and
up to 95 kb 3V to SOX9 (Fig. 8). The combined lacZ expression
patterns mediated by the Sox9 promoter (neural tube and
hindbrain), enhancer E1 (node, notochord, gut, bronchial
epithelium and pancreas), fragments E5–E3/enhancer E3
(CNCCs and inner ear) and enhancer E7 (forebrain and
midbrain) recapitulate many aspects of the complex endoge-
nous Sox9 expression pattern. All four cis-regulatory
sequences initiated lacZ expression at stages very similar to
endogenous Sox9. However, while fragments E5–E3 and
enhancer E1 were able to recapitulate Sox9 expression also at
later stages, both neural enhancers could reproduce only the
early aspect of SOX9 expression (see also below). Elements
E2, E4 and E6 did not show independent enhancer activity.
These elements could be general enhancers that up-regulate an
already specified expression or they could function as silencers.
The presence of multiple cis-regulatory elements between
350 kb 5V and 250 kb 3V to SOX9 has previously been inferred
from expression analyses in mice transgenic for human SOX9-
lacZ yeast artificial chromosomes (YACs) containing variable
amounts of DNA sequences 5V to SOX9 (Wunderle et al.,1998). In accordance with the findings of Wunderle et al.
(1998) that cis-regulatory elements for SOX9 expression in the
neuroectoderm are located between 75 kb 5V and 250 kb 3V to
SOX9, both neural-specific enhancers (E7 located 95 kb 3V to
SOX9 and the Sox9 promoter) reside within this region.
Furthermore, apart from the E3 inner ear enhancer identified
in this study that lies 251 kb upstream of SOX9, Wunderle et al.
(1998) found a weak inner ear enhancer located between 75 kb
5V and 250 kb 3V to SOX9 and an enhancer potentially up-
regulating this expression between 150 kb and 75 kb 5V to
SOX9. Thus, SOX9 expression in the inner ear seems to be
controlled by at least three different widely spaced enhancers.
In contrast to the YAC transgenes that showed robust lacZ
expression in the chondrocytes of the vertebral column,
pharyngeal arches and limbs, we could so far not identify
enhancers for SOX9 expression in chondrocytes. However,
elements E2, E4 and possibly E5 which showed no indepen-
dent enhancer activity could be involved in the up-regulation of
chondrocyte expression. In agreement with this, E2 resides
within an interval (150 kb to 75 kb 5V to SOX9) where up-
regulating enhancers for pharyngeal arch chondrocyte expres-
sion were assumed to exist, and elements E5 and E4 are located
within an interval (350 kb to 200 kb 5V to SOX9) where up-
regulating enhancers for SOX9 expression in chondrocytes of
the limbs and vertebral column were suggested to exist by
Wunderle et al. (1998). The expression pattern of enhancer E1
and the E3-mediated expression in CNCCs could not be
compared with the expression pattern of the YAC transgenes as
the corresponding tissues have not been analyzed by Wunderle
et al. (1998).
Fig. 8. Location of functional enhancers within the SOX9 cis-regulatory domain identified in this study. Three (E3, E1 and E7) of the seven conserved sequence
elements from the human SOX9 locus (E1–E7) analyzed in this study and the 529 bp mouse Sox9 promoter mediated lacZ expression in a tissue-specific manner.
Arrows point to the tissue specificity of enhancers E3, E1 and E7 and of the Sox9 promoter. The expression patterns of these cis-regulatory elements are non-
overlapping. Expression of Sox9 in the node, notochord, in the gut and gut-derived tissues (bronchial epithelium and pancreas) is controlled by enhancer E1. For the
control of Sox9 expression in neural tissues, two cis-regulatory elements have been identified: while E7 directs the early aspect of expression in the telencephalon
and midbrain, the 529 bp Sox9 promoter mediates the early aspect of expression in the hindbrain and spinal cord. Finally, enhancer E3 is responsible for Sox9
expression in cranial neural crest cells and inner ear.
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been shown to be at least partly responsible for the testis-
specific expression of Sox9 in vitro (Kanai and Koopman,
1999). However, we found that the Sox9 promoter can mediate
lacZ expression only in the ventral neural tube/hindbrain in
transgenic mice, suggesting that the Sox9 promoter itself has
no significant testis-specific activity in vivo.
Control of SOX9 expression in neural tissues
We identified two distinct regulators for Sox9 expression in
neural tissues along the anteroposterior (AP) axis. While
enhancer E7 directs reporter gene expression in the telenceph-
alon and midbrain, the 529 bp Sox9 promoter mediates
expression in the hindbrain and spinal cord. Since both neural
enhancers could reproduce only the early aspect of SOX9
expression, these enhancers are most likely involved in the
onset of SOX9 expression in neural tissues, while the
maintenance of SOX9 expression is regulated by so far
unidentified enhancers.
Sox9 has been shown to be a major molecular component in
the ventral neural tube for the switch from neurogenesis to
gliogenesis in mice (Stolt et al., 2003). Mice in which Sox9 has
been inactivated in neural stem cells show an early dramatic
reduction in progenitors of oligodendrocytes and astrocytes and
a concomitant transient increase in motorneurons and V2
interneurons (Stolt et al., 2003). The 529 bp minimal mouse
Sox9 promoter region contains enhancer sequences that, similar
to endogenous SOX9 (Stolt et al., 2003 and this study), initiate
lacZ expression specifically in the ventral neural tube at 9.5
dpc. Since little is known as to what causes the neural stem
cells to switch from neurogenesis to gliogenesis, this enhancer
provides an opportunity to identify the essential transcription
factors that initiate this process. By comparing the SOX9/Sox9promoter sequence with the 190 bp V2 interneuron-specific
GATA2/Gata2 enhancer (Zhou et al., 2000) which mediates
lacZ expression exclusively in the spinal cord and in the
hindbrain, similar to the Sox9 promoter, we could identify
several sequence blocks conserved between human and mouse
(Fig. 6C). The high conservation of these sequences suggests
that they might be important for SOX9 expression in the ventral
neural tube.
SOX9 expression in the node, notochord, gut and gut-derived
tissues is regulated by a common enhancer
Enhancer E1, located 28 kb 5V to SOX9, directs lacZ
expression to the node, notochord, gut, bronchial epithelium
and pancreas, with an expression pattern closely resembling
that of endogenous Sox9 (Ng et al., 1997). Thus, enhancer E1
seems to contain most or all of the cis-regulatory sequences
needed to control Sox9 expression in these tissues. Previously,
we had identified a potential Foxa2 binding site within
enhancer E1 that is well conserved between human, mouse
and Takifugu (Bagheri-Fam et al., 2001) and that differs by
only one base or is identical to the 12 bp Foxa2 consensus
sequence (C/G)AAT(G/A)TTTG(C/T)(C/T)(C/T) (Overdier et
al., 1994, Fig. 6A). In the present study, we found that this
site is even conserved up to the invertebrates Ciona and
Drosophila. Foxa2 is essential for node and notochord
formation in mice and is a good candidate to regulate Sox9
expression via enhancer E1 since it is co-expressed with Sox9
in all tissues in which lacZ expression is mediated by E1
(Monaghan et al., 1993; Ang and Rossant, 1994; Ng et al.,
1997). In the fetal intestinal epithelium, SOX9 expression has
been shown to be dependent on Wnt/beta-catenin signals that
are mediated by the transcription factor TCF4 (Blache et al.,
2004). We could not identify a conserved Tcf/Lef1 binding
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show that beta-catenin physically interacts with Sox17
(essential for endoderm formation) and potentiates its
transcriptional activation on target genes, particularly on
Foxa2. Therefore, the Wnt/beta-catenin signaling pathway
could act indirectly through Foxa2 in the activation of Sox9
in the gut.
The notochordal cells are enveloped within a sheath of
extracellular matrix that contains different collagens (e.g.
Col2a1), proteoglycans and glycoproteins, typically found in
cartilage. Sox9 is essential for chondrogenesis, is expressed in
chondrocytes and in the notochord and directly regulates
Col2a1 through its 48 bp intronic enhancer (Ng et al., 1997;
Lefebvre et al., 1998; Akiyama et al., 2002). In contrast to the
Col2a1 enhancer that is active both in chondrocytes and in
the notochord (Sakai et al., 2001), we found that enhancer E1
is only active in the notochord. This indicates that Sox9 is
controlled by a different set of transcription factors in its
function as a regulator of extracellular matrix genes in
chondrocytes on the one hand and in the notochord on the
other hand. Sox9 expression in the notochord, in the gut and
in gut-derived organs, however, seems to be under the control
of similar regulatory mechanisms. As both the Drosophila
Sox100B gene, the likely precursor of Sox8, Sox9 and Sox10,
and the Drosophila forkhead gene (fkh), the likely precursor
of Foxa1, Foxa2 and Foxa3, are expressed in the gut (Loh
and Russell, 2000; Weigel et al., 1989) and as element E1
with a highly conserved Foxa binding site is already present
in Drosophila (Fig. 6A), we speculate that element E1
originally evolved as a gut-specific enhancer under fkh
control already some 700 million years ago. Later during
evolution, with the appearance of the notochord in Urochor-
dates such as Ciona, which separated from the vertebrate
lineage approximately 550 million years ago and which also
contains an E1 element (Fig. 6A), this element acquired the
function to regulate SoxE expression also in the notochord. In
accordance with an evolutionary early E1-driven expression
of Sox9 in the notochord, the zebrafish sox9b gene has also
been shown to be expressed in the notochord (Li et al., 2002),
and the human enhancer E1 is able to drive reporter gene
expression in the zebrafish notochord (I. Hess, U. Straehle
and G. Scherer, unpublished), demonstrating functional
conservation over at least 400 million years of evolutionary
separation.
To our knowledge, the evolutionary conservation of a cis-
regulatory element between vertebrates and invertebrates has
not been reported so far. Recently, by using a whole-genome
comparison between humans and the pufferfish, T. rubripes,
Woolfe et al. (2005) could identify nearly 1400 highly
conserved non-coding sequences that associate with devel-
opmental regulators. However, no significant matches to any
of these conserved sequences were found in the inverte-
brates Ciona, Drosophila or C. elegans. Our data indicate
that, by a more in-depth analysis, e.g. by visual inspection,
some non-coding, functionally relevant sequences may
indeed be found to be conserved between vertebrates and
invertebrates.Regulation of SOX9 expression in cranial neural crest cells
and in the otic placode/vesicle
In Xenopus, Sox9 is essential for the specification of
CNCCs (Spokony et al., 2002; Lee et al., 2004a) and of the
otic placode (Saint-Germain et al., 2004). Similarly, in
homozygous Sox9 knock-out mice, the population of CNCCs
is drastically reduced, and the development of the otic vesicle
is disrupted from the earliest stages on (Akiyama et al., 2004;
Barrionuevo et al., unpublished). These data suggest that Sox9
has an evolutionarily conserved role in the early development
of both tissues. We found that the highly conserved enhancer
E3 (80% identity over 98 bp between human and Takifugu, Fig.
6B) mediates lacZ expression specifically in CNCCs and in the
otic placode/vesicle, suggesting that also the regulatory
mechanisms activating Sox9 expression in these tissues are
conserved across species. Indeed, within enhancer E3, we
could identify several conserved binding sites for transcription
factors that have important and early functions in cranial neural
crest and inner ear development (Meis/Pbx/Hox1–5, Ap2, Tcf/
Lef1, Ets, Gli/Krox20, Dlx and Otx, Fig. 6B).
In Xenopus, Sox9 expression in CNCCs is regulated by the
Wnt/beta-catenin- and the Fgf signaling pathways (Lee et al.,
2004a) which are both essential and sufficient for neural crest
formation in Xenopus (Villanueva et al., 2002). Similarly, in
chicken, Wnt signals can function as inducers of neural crest
fate (Garcia-Castro et al., 2002), and, in the mouse, Wnt signals
are involved in the regulation of neural crest fate decisions (Lee
et al., 2004b). Sox9 expression in CNCCs in Xenopus is also
dependent on Ap2a which itself is essential for neural crest
formation in Xenopus (Luo et al., 2003; Saint-Germain et al.,
2004). In the mouse, Ap2a is expressed before Sox9 during
neural crest development (Mitchell et al., 1991; Ng et al.,
1997), and, similar to Sox9 knock-out mice (Akiyama et al.,
2004; Barrionuevo et al., unpublished), Ap2/ mosaic knock-
out mice show hypoplasia of the pharyngeal arches (Nottoli et
al., 1998). In accordance with the activation of Sox9 by Ap2a
and by both the Wnt/beta-catenin and the Fgf signaling
pathway, enhancer E3 contains, within a region of only 26
bp, conserved binding sites for Ap2a (only conserved between
human and mouse), Tcf/Lef1 (transcription factor that activates
Wnt/beta-catenin dependent target genes by interaction with
beta-catenin) and Ets (transcription factor involved in the
activation of Fgf-dependent target genes) (Fig. 6B). It is thus
possible that these factors regulate Sox9 expression across
species and that this regulation is direct. Indeed, by analyzing
E5–E3-directed lacZ expression in mouse embryos with
targeted inactivation of beta-catenin in the dorsal neural tube,
we could show that beta-catenin is essential for lacZ expression
in CNCCs migrating to and within the first pharyngeal arch.
Future studies will have to show if this regulation by beta-
catenin is direct or indirect. LacZ expression in the second and
third pharyngeal arches, however, was only mildly affected in
beta-catenin-deficient mice.
Our data indicate that distinct regulators control Sox9
expression in NCCs along the AP axis. First, enhancer E3
mediates lacZ expression exclusively in cranial NCCs migrat-
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expressed in the more anterior located forebrain and midbrain
cranial NCCs as well as in the more posterior located trunk
NCCs (Ng et al., 1997; Zhao et al., 1997). Second, as described
above, regulation of enhancer fragments E5–E3 in the first
pharyngeal arch differs from its regulation in the second and
third pharyngeal arches. A possible explanation for this
complex regulation is indicated by the high accumulation of
conserved potential binding sites for homeodomain transcrip-
tion factors within enhancer E3. We found two binding regions
for the ternary protein complex Meis/Pbx/Hox, in which both
Hox binding sites are specific for the most anterior expressed
Hox groups 1–5 (Shen et al., 1997), two potential binding sites
for the Otx homeobox proteins and one potential binding site
for Dlx. These homeodomain transcription factors display
distinct expression domains in CNCCs along the AP and
dorsoventral (DV) axis of the developing vertebrate head,
thereby providing positional identity to CNCCs (see Santagati
and Rijli, 2003, for review). While Hox genes are expressed in
CNCCs of the second pharyngeal arch and at more caudal
levels, Otx2 is expressed in the Hox-negative CNCCs that are
rostral to the second pharyngeal arch (Kimura et al., 1997).
Along the dorsoventral axis of the pharyngeal arches,
molecular identity is provided by the nested expression of
Dlx genes (Panganiban and Rubenstein, 2002). We hypothesize
that a specific combination of these homeodomain transcription
factors binding to enhancer E3 restricts reporter gene expres-
sion to CNCCs migrating into the pharyngeal arches. More-
over, since Hox proteins are not expressed in CNCCs of the
first pharyngeal arch where lacZ expression is mainly
dependent on beta-catenin, but in CNCCs of the second and
third pharyngeal arch where lacZ expression is independent of
beta-catenin, we speculate that lacZ expression in the second
and third pharyngeal arches could be largely controlled by Hox
proteins. The importance of Meis/Pbx/Hox1–5 sites for the
expression in rhombomere R4/second pharyngeal arch neural
crest cells has been well documented for the Hoxb2-R4
enhancer that mediates the cross-regulation of Hoxb2 by
Hoxb1 in vivo (Jacobs et al., 1999).
We also found a potential binding site for Gli or Krox20.
The Gli protein family members are transcriptional mediators
of Sonic hedgehog (Shh) signaling. Shh is required for the
proliferation and survival of CNCCs (Ahlgren and Bronner-
Fraser, 1999; Jeong et al., 2004). Shh null mice show loss of
the pharyngeal arches and frontonasal mass (Chiang et al.,
1996), and inhibition of Shh signaling in the chick results in
reduced pharyngeal arch structures and frontonasal tissue
(Ahlgren and Bronner-Fraser, 1999), very similar to the Sox9
knock-out mice (Akiyama et al., 2004; Barrionuevo et al.,
unpublished). Krox20 is specifically expressed in the uneven
rhombomeres R3 and R5 that do not generate CNCCs and is
essential for their identity (Voiculescu et al., 2001). A potential
function for Krox20 could be to repress Sox9 expression in the
future rhombomeres R3 and R5, so that these rhombomeres
cannot generate neural crest cells.
Apart from their essential functions in the formation of
neural crest cells, Wnt and Fgf signaling pathways have beenimplicated in the specification of the otic placode in mouse,
chicken, Xenopus and zebrafish embryos (Ladher et al., 2000;
Maroon et al., 2002; Liu et al., 2003; Wright and Mansour,
2003). In Xenopus, Sox9 expression in the otic placode is
regulated by both the Wnt/beta-catenin and Fgf signaling
pathway and is maintained by Dlx3 (Saint-Germain et al.,
2004). Similarly, Sox9 expression in the otic placode in
zebrafish is dependent (sox9a) on or is up-regulated (sox9b)
by Fgf3/Fgf8 and sox9a/sox9b and dlx3b/dlx4b cross-regulate
their expression (Liu et al., 2003). In mice and in humans, Dlx
proteins have also been implicated in inner ear development.
Dlx5/ mice show inner ear defects (Acampora et al., 1999),
and mutations in human DLX3 result in hearing problems
(Price et al., 1998). The presence of highly conserved binding
sites for Tcf/Lef1, Ets and Dlx within enhancer E3 suggests
that the regulation of Sox9 by these factors is direct and
evolutionarily conserved up to human and mouse.
In conclusion, our study provides another example of the
validity of the comparative genomics approach for the
identification of conserved and functional regulatory elements
located at considerable distances from the gene they control.
That the long-range SOX9 enhancers we have characterized
only account for a subset of the complex spatiotemporal
expression pattern of this developmental gene is not too
surprising. Future work will need to identify still elusive
enhancers such as those responsible for Sox9 expression during
chondrogenesis and testogenesis. Nevertheless, the cis-regula-
tory elements presented and discussed here will already
provide an entry point to the characterization of some of the
transcription factors controlling the expression of Sox9,
allowing for a better definition of the regulatory network that
specifies cells/organs such as cranial neural crest cells, the otic
placode and glial cells in humans or mice.
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